QGEN · Qiagen NV
Price
Snapshot
50 fields · last close| Market Cap | $8.96B |
| P/E | 21.89 |
| Float | 205.3M |
| Beta | 0.60 |
| Volatility | 14.9% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 76 |
| Price | 43.47 |
| Change | −0.02% |
| Prev Close | 43.48 |
| Open | 43.19 |
| Day Low | 42.79 |
| Day High | 43.66 |
| Avg Vol | 3 |
| Avg $ Vol | $116.2M |
| 52W High | 57.81 |
| 52W Low | 32.53 |
| 52W Pos | 43.3% |
| From High | −24.81% |
| From Low | +33.63% |
| Max DD 1Y | −41.38% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.17% |
| SMA 50 | +3.76% |
| SMA 200 | +1.73% |
| RSI (14) | 53.5 |
| Vol 30D | 33.2% |
| Vol 90D | 33.6% |
| 1Y Range | 33–58 |
| Daily bars | 507 |
| Perf Week | +0.84% |
| Perf Month | +4.17% |
| Perf Quarter | +18.51% |
| Perf Half Y | −2.42% |
| Perf Year | −7.59% |
| Perf YTD | −3.81% |
| Prev Day | −0.02% |
| Clavix | B+ |
| Debt / Eq | 0.44 |
| Curr Ratio | 3.90 |
| Int Cover | 507.1× |
| FCF Margin | 21.2% |
| Rev Growth | +0.3% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 4 / 19 |
Clavix risk grade
regraded every trading dayQGEN grades B+, 76 of 100. Steadiest on Macro Resilience (67), most exposed on News Sentiment (59, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 4 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| QGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.60 | 1.19 |
| Volatilityannualized | 14.9% | 29.7% |
| Max drawdown, past yearworst peak-to-trough fall | −41.4% | — |
| Typical daily movemedian absolute daily change | 0.94% | — |
| Days beyond ±3%of the last 252 sessions | 177% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| QGEN | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.60 | 1.19 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| QGEN | |
|---|---|
| 1 week | +0.8% |
| 1 month | +4.2% |
| Year to date | −3.8% |
| 1 year | −7.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| QGEN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 9 Jul |
| Average score0 most bearish, 100 most bullish | 63 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 4 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| QGEN | |
|---|---|
| Revenue growthyear over year | +0.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Life Sciences Tools & Services
19 companies| Metric | QGEN | Sector spread | Median |
|---|---|---|---|
| Beta | 0.60 | 1.19 | |
| Volatility | 14.9% | 29.7% | |
| P/E | 21.89 | 36.46 | |
| Debt / equity | 0.44 | 0.51 | |
| Current ratio | 3.90 | 1.89 | |
| FCF margin | 21.2% | 18.8% | |
| Interest coverage | 507.1× | 3.5× |
Recent news
most recent scored articles · the chip is the article’s score · click to openQiagen's Q2 2026 adjusted earnings per share and net sales came in above what analysts had expected, and management confirmed its full year outlook. The stock closed at $43.47, down 0.89% on the day but up 18.51% over the prior 90 days.
Qiagen launched a new automated DNA/RNA extraction platform called QIAsymphony Connect in late August 2026, announced Jon Pratt as its new CEO starting September 1, and reported Q2 2026 results that beat analyst expectations while reaffirming its guidance.
Qiagen received FDA clearance on August 10 for its QIAstat-Dx BCID GPF Plus AMR Panel, marking its first entry into the U.S. bloodstream infection testing market. The company also reported Q2 2026 net sales of $535 million (flat year-over-year at constant exchange rates) and reaffirmed its full-year guidance, while announcing Jonathan Pratt will replace Thierry Bernard as CEO on September 1.
QIAGEN has commercially launched QIAsymphony Connect, an IVD-compliant (cleared for use in clinical diagnostic testing) platform that automates nucleic acid extraction (pulling DNA or RNA out of patient samples) for clinical laboratories. The new product extends the existing QIAsymphony line, which already has more than 3,300 units installed worldwide, and is designed to help labs standardize extraction across different testing workflows.
QIAGEN announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. The new platform builds on the existing QIAsymphony system, which has more than 3,300 placements worldwide, and is designed to help clinical labs standardize extraction across different testing workflows.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BRKR | Bruker Corp | C- | $8.91B | — | 1.26 | Compare |
| RGEN | Repligen Corp | B- | $9.46B | 227.70 | 1.14 | Compare |
| TXG | 10X Genomics Inc | C- | $8.16B | — | 2.07 | Compare |
| AVTR | Avantor Inc | B- | $10.13B | — | 0.98 | Compare |
| TECH | Bio-Techne Corp | B- | $11.36B | 62.46 | 1.30 | Compare |
| TEM | Tempus AI Inc | D- | $11.66B | — | 2.34 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $13.77B | — | 1.41 | Compare |
| RVTY | Revvity Inc | B | $14.53B | 61.17 | 1.11 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.